Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Headline
Two individuals have died in Michigan in connection to the current multistate cyclosporiasis outbreak, the Michigan Department of Health and Human Services…
Headline
The AHA’s Living Learning Network, in partnership with the Centers for Disease Control and Prevention, July 22 released “Rural Sepsis Care in Action: Real-…
Headline
The Centers for Disease Control and Prevention July 14 released an advisory on the growing cyclosporiasis cases across the U.S. The advisory said that the…
Headline
The Centers for Disease Control and Prevention has reported 843 cases of cyclosporiasis across 31 states, with 86 people hospitalized. State health departments…
Headline
Angela Hewlett, M.D., professor of infectious diseases at the University of Nebraska Medical Center and medical director of the Nebraska Biocontainment Unit,…
Headline
The Administration for Strategic Preparedness and Response June 16 announced the launch of the Digital Stockpile and Manufacturing Response Network Challenge,…